Efficacy and Safety of Bimekizumab in Patients with Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies
ACR Open Rheumatol. 2024 Jul 30 doi: 10.1002/acr2.11727 Epub ahead of print
McInnes et al. reported that bimekizumab demonstrated sustained efficacy and safety over 52 weeks in patients with psoriatic arthritis (PsA), regardless of concomitant methotrexate (MTX) use. Both bimekizumab groups (with and without MTX) showed similar improvements in achieving ACR50 and PASI100 responses.
The study included patients from two Phase 3 trials, BE OPTIMAL and BE COMPLETE, assessing bimekizumab’s efficacy and safety in biologic DMARD-naïve PsA patients and those with prior inadequate response to TNF inhibitors, respectively. The primary aim was to evaluate the 52-week outcomes for bimekizumab with or without MTX.
Keywords:
